This 2023 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly semaglutide (2.4 mg) in 201 adolescents aged 12 to
This 2015 phase II, double-blind, randomized controlled trial assessed the efficacy and safety of beloranib, a methionine aminopeptidase 2 (MetAP2) inhibitor, in 147 obese adults over 12 weeks. Participants received subcutaneous beloranib at doses of 0.6, 1.2, or 2.4 mg, or placebo, without dietary or exercise interventions. Beloranib induced dose-dependent
This 2018 systematic review and network meta-analysis evaluated the impact of FDA-approved weight-loss medications—phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat—on cardiometabolic risk factors in obese adults. Analyzing 28 randomized controlled trials encompassing 29,018 participants, the study found that these medications led to modest reductions in fasting blood glucose (mean decrease of
This 2019 randomized controlled trial evaluated the efficacy of combining intensive behavioral therapy (IBT) with liraglutide 3.0 mg, with or without a 12-week meal replacement diet, in 150 adults with obesity over 52 weeks. Participants were assigned to one of three groups: IBT alone, IBT plus liraglutide, or IBT plus
This 2-year randomized, double-blind, placebo-controlled trial assessed the long-term safety, tolerability, and efficacy of once-daily subcutaneous liraglutide (1.2–3.0 mg) in 564 obese adults (BMI 30–40 kg/m²) across 19 European centers. After a 20-week core phase, 398 participants entered a 2-year extension. At 1 year, those on liraglutide 3.0 mg lost
This 56-week, randomized, placebo-controlled trial evaluated the efficacy and safety of combining sustained-release naltrexone (32 mg/day) and bupropion (360 mg/day) with intensive behavior modification (BMOD) in 793 obese adults (mean BMI 36.5 ± 4.2 kg/m²). Participants were randomized in a 1:3 ratio to receive either placebo + BMOD (N=202) or
This pooled analysis of two prospective observational registry studies evaluated the long-term effects of testosterone undecanoate therapy in 156 obese hypogonadal men with type 2 diabetes mellitus (T2DM) over a period of up to 6 years. Testosterone treatment led to significant and sustained reductions in weight (mean loss of 17.49
This observational study examined the relationship between fecal short-chain fatty acids (SCFAs), gut microbiota diversity, gut permeability, and cardiometabolic outcomes such as obesity and hypertension. Higher fecal SCFA levels were associated with reduced gut microbiota diversity, increased gut permeability markers, and greater cardiometabolic risk factors. These findings suggest that elevated
This observational study investigated the effects of a 10-hour time-restricted eating (TRE) window over 12 weeks in 19 adults with metabolic syndrome (MetS), most of whom were also on statins or antihypertensive medications. TRE led to significant improvements, including an average weight loss of 3.3 kg, reduced waist circumference, BMI,
This umbrella review analyzes the effects of polyphenols on anthropometric measures and cardiometabolic risk factors in individuals with overweight and obesity. Polyphenol supplementation led to significant reductions in body weight, body mass index (BMI), waist circumference, and fasting blood glucose levels. Additionally, improvements were seen in cholesterol levels, blood pressure,
